Vasomotor Symptoms Market Size is Growing at a CAGR of 7% | Some of the Major Players are KaNDy Therapeutics, Fervent Pharmaceuticals, Astellas…

"The increase in Market Size is a direct consequence of increasing prevalent population of Vasomotor Symptoms patients in the 7MM, along with this emerging market focus on the targeted therapies, among which NK1/3 antagonist is the most hopeful target that is likely to shift the market."

LAS VEGAS , March 16, 2020 /PRNewswire/ -- DelveInsight has announced the addition of a new market research report on "Vasomotor symptoms (Hot flashes/Night sweats) Market Insights, Epidemiology and Market Forecast-2030" to its offerings. The report proffers in-depth Vasomotor symptoms Market Analysis, 11 years Market Size Forecast, detailed Epidemiology analysis and 11-year Forecast, Emerging Drugs Market Uptake and information related to Leading Companies along with the Competitive Analysis edge.

Some key highlights from the report:

Click here to getVasomotor Symptomsmarketsample pages:https://www.delveinsight.com/sample-request/vasomotor-symptoms-market

Vasomotor Symptoms are one of the main symptoms of menopause that principally include hot flashes and night sweats during menopause and occurs in the majority of women across the globe. A woman with Vasomotor Symptoms experiences abundant heat accompanied by sweating and flushing, especially around head, neck, chest, and upper back region. This results from temperature dysfunction that occurs due to changes in gonadal hormones.

The Vasomotor Symptoms Epidemiology in report is segmented on the basis of Vasomotor symptoms prevalence; Hot Flashes associated with Post Menopause Prevalent Cases; Severity-specific cases of Hot flashes (Mild, Moderate and Severe) in post-menopause; Diagnosed and Treatable Cases of Vasomotor symptoms.

Vasomotor Symptoms Market

The current Hot Flashes Associated with menopause therapeutic landscape in the US can be bifurcated into two main categories based on the classes of drug. These are Hormonal Therapies and Non-hormonal Therapies.

Systemic hormone replacement therapy, with estrogen alone or in combination with a progestin, is the most beneficial therapy for vasomotor symptoms related to menopause.Hormone therapy consists of estrogen-only therapy or combined-estrogen-progestogen therapy. It is the most common form of vasomotor symptoms treatment. At present, there are almost 100 different combinations of estrogen-only, progestin, and combination hormone therapies available.

On the other hand, non-hormonal therapies include specific antidepressant agents, gabapentin, and clonidine that are used for the vasomotor symptoms associated with menopause treatment. Brisdelle is the first and only non-hormonal antidepressant approved for the Vasomotor Symptoms treatment.

Along with this, due to the side effects of the hormonal therapy, emerging market focuses on the targeted therapies, among which NK1/3 antagonist is the most hopeful target that is anticipated to shift the market to the next level.

Many potential systemic therapies are being investigated for the management of the disease. It is expected that Hot Flashes associated with post-menopause market size of currently available therapies (both hormonal and non-hormonal) for the treatment is expected to increase due to the launch of upcoming therapies in the forecast period of 20202030. Moreover, the ratio of hormonal to non-hormonal therapies prescribed for hot flashes treatment will decrease significantly.

Story continues

Click here to receive a sample report onVasomotor SymptomsMarket Trends.

There are a few approved drugs for the management of the disease. The launch of the emerging therapies is expected to impact the Vasomotor Symptoms treatment market scenario in the upcoming years:-

Drugs covered in the reportare:-

and many others

TheVasomotor SymptomsMarket Key Players are:-

and many others

Click here to getVasomotor Symptomsmarketsample pages:https://www.delveinsight.com/sample-request/vasomotor-symptoms-market

Vasomotor Symptoms Reimbursement Scenario:-

The reimbursement will have a positive impact on both- during the late stages of product development and well after product launch. In the report, the reimbursement is taken into consideration to identify economically attractive indications and market opportunities.

Vasomotor Symptoms KOL Opinions:-

KOLs and SME's opinions benefit in understanding current and emerging therapies treatment patterns. This will help the clients in identifying the overall scenario of the Vasomotor symptoms market trends and the unmet needs in potential upcoming novel treatment.

Click here to get sample pages:https://www.delveinsight.com/sample-request/vasomotor-symptoms-market

Reasons to buy

Key Topics Covered:

1. Key Insights

2. Vasomotor Symptoms Market Overview at a Glance

3. Executive summary

4. Organizations

5. Vasomotor Symptoms Epidemiology and Market Methodology

6. Vasomotor Symptoms associated with menopause Disease Background and Overview

7. Vasomotor Symptoms Epidemiology and Patient Population

8. Total Vasomotor Symptoms in Post-menopause Prevalent cases in 7MM

9. Country Wise Hot Flashes Associated with Post-menopause Epidemiology

9.1. United States

9.2. EU5 Countries

9.3. Germany

9.4. France

9.5. Italy

9.6. Spain

9.7. United Kingdom

9.8. Japan

10. Vasomotor Symptoms Treatment Algorithm, Current Treatment, and Medical Practices

11. Unmet Needs

12. Vasomotor Symptoms Marketed drugs by class

12.1. Hormonal Therapies

12.2. Non-hormonal Therapies

12.3. Recent additions in Hormonal therapies

12.4. Bijuva: TherapeuticsMD

13. Vasomotor Symptoms Emerging Therapies

13.1. Key Cross Competition

13.2. Hormonal Based therapies

13.3. Donesta: Mithra Pharmaceuticals (Donesta Biosciences)

13.4. Non-Hormonal Based therapies

13.5. NT-814: KaNDy Therapeutics

13.6. FP-101: Fervent Pharmaceuticals

13.7. Fezolinetant: Astellas Pharma

13.8. Other Potential therapies

13.9. SJX 653: Sojournix

13.10. MT-8554: Mitsubishi Tanabe Pharma

14. Hot Flashes 7 Major Market Analysis

15. Seven Major Market Outlook

15.1. United States Market Size

15.2. Germany

15.3. France

15.4. Italy

15.5. Spain

15.6. United Kingdom

15.7. Japan

16. Market Drivers

17. Market Barriers

18. SWOT

19. Case Studies

20. KOL Views

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Request a Webex Demo to get a walk-through of the report:https://www.delveinsight.com/sample-request/vasomotor-symptoms-market

AboutDelveInsight

DelveInsightis a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Related Reports:-

Contact us:Shruti Thakurinfo@delveinsight.com+91-9650213330DelveInsight

View original content:http://www.prnewswire.com/news-releases/vasomotor-symptoms-market-size-is-growing-at-a-cagr-of-7--some-of-the-major-players-are-kandy-therapeutics-fervent-pharmaceuticals-astellas-pharma-sojournix-mitsubishi-tanabe-pharma-301024585.html

SOURCE DelveInsight Business Research LLP

Continued here:
Vasomotor Symptoms Market Size is Growing at a CAGR of 7% | Some of the Major Players are KaNDy Therapeutics, Fervent Pharmaceuticals, Astellas...